BOCHGR:ATHEXBank of Cyprus Holdings Plc Analysis
Data as of 2026-05-20 - not real-time
€9.36
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Bank of Cyprus trades at €9.36, delivering a trailing P/E of 8.4 versus the industry average of 16.5, indicating a clear valuation discount. The price‑to‑book of 1.34 sits just above book value, reinforcing the undervalued picture. A dividend yield of 5.4% with a 61% payout ratio is backed by €9.28 bn of cash and a modest €1.37 bn debt load, suggesting sustainability. Operating margins of 57.7% and a profit margin of 47% demonstrate strong earnings efficiency. Revenue is growing at 6.3% YoY, while ROE of 16% signals solid shareholder returns.
Technically, the stock sits just below its 20‑day SMA (9.40) but comfortably above the 200‑day SMA (8.34), confirming a bullish longer‑term trend. Current price is near the identified support at €9.07 and well under the 52‑week high of €9.98, leaving upside potential of roughly 17%. The RSI of 51 indicates neutral momentum, while a bearish MACD histogram hints at short‑term caution. Volume is on an increasing trend, improving liquidity, and the beta of 0.59 points to lower market volatility. Recent news of a €650 million covered bond amendment and a notable shareholding change underscores active capital management without altering the fundamental outlook. Combined with a “Extreme Greed” sentiment index reading, the environment favors investors seeking yield and value. Overall, the blend of attractive valuation, robust cash generation, and modest risk makes the stock a compelling buy across horizons.
Technically, the stock sits just below its 20‑day SMA (9.40) but comfortably above the 200‑day SMA (8.34), confirming a bullish longer‑term trend. Current price is near the identified support at €9.07 and well under the 52‑week high of €9.98, leaving upside potential of roughly 17%. The RSI of 51 indicates neutral momentum, while a bearish MACD histogram hints at short‑term caution. Volume is on an increasing trend, improving liquidity, and the beta of 0.59 points to lower market volatility. Recent news of a €650 million covered bond amendment and a notable shareholding change underscores active capital management without altering the fundamental outlook. Combined with a “Extreme Greed” sentiment index reading, the environment favors investors seeking yield and value. Overall, the blend of attractive valuation, robust cash generation, and modest risk makes the stock a compelling buy across horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- price near support level of €9.07
- high dividend yield of 5.4%
- valuation discount vs industry peers
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- target upside of ~17% toward €10.97
- strong operating margins and cash position
- sustainable dividend payout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- solid ROE and consistent earnings growth
- low leverage and ample cash reserves
- stable dividend stream for income investors
Key Metrics & Analysis
Financial Health
Revenue Growth6.30%
Profit Margin47.21%
P/E Ratio8.4
ROE16.18%
ROA1.75%
P/B Ratio1.3
Industry P/E16.5
Technical Analysis
TrendBullish
RSI51.1
Support€9.07
Resistance€9.98
MA 20€9.40
MA 50€9.02
MA 200€8.34
MACDBearish
VolumeIncreasing
Fear & Greed Index89.14
Valuation
Target Price€10.97
Upside/Downside17.17%
GradeUndervalued
TypeBlend
Dividend Yield5.39%
Risk Assessment
Beta0.59
Volatility36.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.